Analysts’ Viewpoint
The global inhaled nitric oxide delivery system market is driven by rise in prevalence of respiratory diseases across the globe. Increase in the geriatric population suffering from respiratory conditions is expected to drive the demand for these systems and other advanced medical treatments in the next few years.
Technological advancements in inhaled nitric oxide delivery systems, such as the development of portable and easy-to-use devices that can deliver precise concentrations of inhaled nitric oxide (INO) to patients, present significant opportunities in the market.
Inhaled nitric oxide delivery systems have been used to treat patients with severe respiratory distress due to COVID-19. INO has proven to be effective at improving oxygenation and reducing inflammation in the lungs, which could help reduce the severity of COVID-19 and improve patient outcomes. Rise in adoption of INO system as a better noninvasive treatment option, increase in awareness about INO therapies, and favorable regulatory environment are projected to drive the global inhaled nitric oxide delivery system market value in the next few years.
Inhaled nitric oxide is a medical gas used to treat various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). It works by dilating blood vessels in the lungs, which could help improve respiratory function. Inhaled nitric oxide delivery systems consist of a small, portable device that generates and delivers a precise concentration of INO to a patient through a nasal cannula or face mask.
Increase in incidence of persistent pulmonary hypertension of the newborn (PPHN) & other respiratory conditions and technological advancements in INO delivery systems are expected to accelerate market expansion.
Inhaled nitric oxide is also used to treat hypoxemic respiratory failure in infants and children. This condition occurs when there is not enough oxygen in the blood. It could also be caused by various underlying conditions such as asthma, pneumonia, and bronchiolitis. INO works by relaxing the muscle in the walls of the blood vessels in the lungs, which allows blood to flow more freely, and increases the amount of oxygen that is delivered to the body's tissues.
Prevalence rate of hypoxemic respiratory failure is increasing among pediatric patients due to factors such as lifestyle changes, infections, increasing environmental pollution, and chronic illnesses. INO delivery system is an effective treatment for hypoxemic respiratory failure in infants and children. These factors are anticipated to bolster global inhaled nitric oxide delivery system market share in the next few years.
Increase in demand for noninvasive treatments, such as inhaled nitric oxide (INO), is likely to increase inhaled nitric oxide delivery system market size. Noninvasive treatments are generally well-tolerated and have fewer side-effects than more invasive treatments, which could make them more appealing to patients and healthcare providers. This could lead to increase in demand for noninvasive treatments such as INO, and consequently, propel the demand for nitric oxide delivery devices.
Usage of inhaled nitric oxide delivery devices allows for continuous administration of the gas, which could be beneficial for patients with severe or persistent hypoxemia. This could make INO delivery system a desirable alternative to more invasive treatments, such as mechanical ventilation, which could be more disruptive to the daily routines of patients.
Elderly people are more prone to respiratory disorders and could be sensitive to the side-effects of invasive treatments, which increases the demand for noninvasive treatment. This, in turn, is propelling inhaled nitric oxide delivery system market development.
In terms of type, the pediatrics segment accounted for the largest market share in 2021. Neonatal and baby respiratory diseases are treated with inhaled nitric oxide. These diseases could include bronchopulmonary dysplasia (BPD), a chronic lung disorder that can appear in preterm infants, and persistent pulmonary hypertension of the newborn (PPHN), a dangerous condition that develops when a newborn's blood pressure in the lungs is excessively high. Inhaling nitric oxide has proven to be useful in treating these problems in babies and young children. Therefore, demand for inhaled nitric oxide delivery systems is high among the pediatric population.
Based on application, the hypoxemic respiratory failure treatment segment accounted for largest global inhaled nitric oxide delivery system market share in 2021. INO delivery system is often used in hypoxemic respiratory failure cases because it can be effective at increasing oxygenation in the body. High incidence of hypoxemic respiratory failure, effectiveness of inhaled nitric oxide in treating the condition, and availability of inhaled nitric oxide delivery systems are bolstering the hypoxemic respiratory failure treatment segment.
In terms of end-user, the hospitals segment held prominent share of the global market in 2021. Hospitals are often the first point of contact for patients with respiratory conditions that require treatment with inhaled nitric oxide. These settings often have the necessary infrastructure and personnel in place to manage storage, handling, and administration of inhaled nitric oxide delivery systems, which could be complex and specialized.
North America is projected to dominate the global market during the forecast period. This is ascribed to high prevalence of respiratory disorders, such as asthma and chronic obstructive pulmonary disease (COPD), in the region. Moreover, North America has the highest healthcare expenditure in the world. This is expected to augment the market in the region.
Europe is the fastest-growing market for inhaled nitric oxide delivery systems. Increase in advancements in inhaled nitric oxide delivery systems, improved patient outcomes, and rise in awareness about treatment with the systems are driving the market in the region.
Asia Pacific is likely to capture significant market share in the next few years. Efforts taken by governments and healthcare organizations to improve access to and availability of INO delivery systems and treatments, especially in rural and underserved areas, is driving market expansion in the region.
The global inhaled nitric oxide delivery system market is fragmented, with the presence of a large number of manufacturers. Key players operating in the market are Mallinckrodt, Santair AE, VERO Biotech, Linde plc, Beyond Air, Inc., SLE, Bellerophon Therapeutics, Air Liquide Healthcare, Circassia Pharmaceuticals, and International Biomedical.
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, product portfolio, strategies, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 299.0 Mn |
|
Forecast Value in 2031 |
More than US$ 497.4 Mn |
|
CAGR - 2022–2031 |
5.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
.Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
The global market was valued at US$ 299.0 Mn in 2021
It is projected to reach more than US$ 497.4 Mn by 2031
It is anticipated to be 5.4% from 2022 to 2031
The pediatric segment held more than 80.0% share in 2021
North America is expected to account for the largest share from 2022 to 2031
Mallinckrodt, Santair AE, VERO Biotech, Linde plc, Beyond Air Inc., SLE, Bellerophon Therapeutics, Air Liquide Healthcare, Circassia Pharmaceuticals, and International Biomedical.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inhaled Nitric Oxide Delivery System Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of applications of iNO in pediatric as well as in adults
5.2. Technological Advancements
5.3. Disease prevalence and incidence globally with key countries
5.4. Covid-19 Impact Analysis
6. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Pediatric
6.3.2. Adult
6.4. Market Attractiveness Analysis, by Type
7. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Hypoxemic Respiratory Failure Treatment
7.3.2. Acute Vasoreactivity Testing
7.3.3. Pulmonary Hypertension (PH) Treatment
7.3.4. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East
9.3. Market Attractiveness Analysis, by Region
10. North America Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Pediatric
10.2.2. Adult
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Hypoxemic Respiratory Failure Treatment
10.3.2. Acute Vasoreactivity Testing
10.3.3. Pulmonary Hypertension (PH) Treatment
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Pediatric
11.2.2. Adult
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Hypoxemic Respiratory Failure Treatment
11.3.2. Acute Vasoreactivity Testing
11.3.3. Pulmonary Hypertension (PH) Treatment
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Pediatric
12.2.2. Adult
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Hypoxemic Respiratory Failure Treatment
12.3.2. Acute Vasoreactivity Testing
12.3.3. Pulmonary Hypertension (PH) Treatment
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Pediatric
13.2.2. Adult
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Hypoxemic Respiratory Failure Treatment
13.3.2. Acute Vasoreactivity Testing
13.3.3. Pulmonary Hypertension (PH) Treatment
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Pediatric
14.2.2. Adult
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Hypoxemic Respiratory Failure Treatment
14.3.2. Acute Vasoreactivity Testing
14.3.3. Pulmonary Hypertension (PH) Treatment
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & South Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Mallinckrodt
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Santair AE
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. VERO Biotech
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Linde plc
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Beyond Air, Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. SLE
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Bellerophon Therapeutics
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Air Liquide Healthcare
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. International Biomedical
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Circassia Pharmaceuticals
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 02: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 03: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 07: North America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 08: North America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 11: Europe Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 12: Europe Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 15: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 16: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 19: Latin America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Material 2017‒2031
Table 20: Latin America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 23: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 24: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Inhaled Nitric Oxide Delivery System Market Value Share, by Type, 2021
Figure 03: Global Inhaled Nitric Oxide Delivery System Market Value Share, by Application, 2021
Figure 04: Global Inhaled Nitric Oxide Delivery System Market Value Share, by End-user, 2021
Figure 05: Global Inhaled Nitric Oxide Delivery System Market Value Share, by Region, 2021
Figure 06: Global Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 07: Global Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type, 2022–2031
Figure 08: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn), by Pediatric, 2017‒2031
Figure 09: Global Inhaled Nitric Oxide Delivery System Market Value (US$ Mn), by Adult, 2017‒2031
Figure 10: Global Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application, 2021 and 2031
Figure 11: Global Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application, 2022–2031
Figure 12: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Hypoxemic Respiratory Failure Treatment, 2017–2031
Figure 13: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Acute Vasoreactivity Testing, 2017–2031
Figure 14: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Pulmonary Hypertension (PH) Treatment, 2017–2031
Figure 15: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Others, 2017–2031
Figure 16: Global Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user 2021 and 2031
Figure 17: Global Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user 2022–2031
Figure 18: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 19: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Ambulatory Surgical Centers, 2017–2031
Figure 20: Global Inhaled Nitric Oxide Delivery System Market Revenue (US$ Mn), by Others, 2017–2031
Figure 21: Global Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Region, 2021 and 2031
Figure 22: Global Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Region, 2022–2031
Figure 23: North America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 24: North America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Country, 2021 and 2031
Figure 25: North America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Country, 2022–2031
Figure 26: North America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 27: North America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type 2022–2031
Figure 28: North America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application, 2021 and 2031
Figure 29: North America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application 2022–2031
Figure 30: North America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user, 2021 and 2031
Figure 31: North America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user, 2022–2031
Figure 32: Europe Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 33: Europe Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 34: Europe Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 35: Europe Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 36: Europe Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type, 2022–2031
Figure 37: Europe Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application 2021 and 2031
Figure 38: Europe Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application 2022–2031
Figure 39: Europe Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user, 2021 and 2031
Figure 40: Europe Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user, 2022–2031
Figure 41: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 42: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 43: Asia Pacific Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 44: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 45: Asia Pacific Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type, 2022–2031
Figure 46: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application, 2021 and 2031
Figure 47: Asia Pacific Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application, 2022–2031
Figure 48: Asia Pacific Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user, 2021 and 2031
Figure 49: Asia Pacific Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user, 2022–2031
Figure 50: Latin America Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 51: Latin America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 52: Latin America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Latin America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 54: Latin America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type, 2022–2031
Figure 55: Latin America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application, 2021 and 2031
Figure 56: Latin America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application, 2022–2031
Figure 57: Latin America Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user, 2021 and 2031
Figure 58: Latin America Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user, 2022–2031
Figure 59: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value (US$ Mn) Forecast, 2017–2031
Figure 60: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 61: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 62: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Type, 2021 and 2031
Figure 63: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Type, 2022–2031
Figure 64: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by Application, 2021 and 2031
Figure 65: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by Application, 2022–2031
Figure 66: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Value Share Analysis, by End-user, 2021 and 2031
Figure 67: Middle East & Africa Inhaled Nitric Oxide Delivery System Market Attractiveness Analysis, by End-user, 2022–2031
Figure 68: Company Share Analysis
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Inhaled Nitric Oxide Delivery System Market
